Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 (NOMID) is a rare genetic disorder that is characterized by recurrent episodes of inflammation in multiple organs and tissues. It is caused by a mutation in the gene that codes for interleukin-18 (IL-18), a cytokine involved in the body's immune response. Symptoms of NOMID include fever, rash, joint pain, eye inflammation, and neurological problems. Treatment typically involves medications to reduce inflammation and suppress the immune system.

The symptoms of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 can vary from person to person, but may include:

-Fever

-Rash

-Joint Pain and swelling

-Abdominal pain

-Diarrhea

-Vomiting

-Lethargy

-Failure to thrive

-Liver and/or kidney inflammation

-Anemia

-Eye inflammation

-Neurological symptoms such as seizures, developmental delay, and/or hearing loss

The exact cause of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 is unknown. However, it is believed to be caused by a genetic mutation in the IL18RAP gene, which is responsible for producing the IL18 receptor. This mutation results in an overproduction of IL18, which can lead to inflammation and other symptoms associated with the disease.

1. Corticosteroids: Corticosteroids are the mainstay of treatment for neonatal-onset severe multisystemic autoinflammatory disease with increased IL18. They can reduce inflammation and help control symptoms.

2. Anakinra: Anakinra is a recombinant form of the human interleukin-1 receptor antagonist (IL-1Ra). It is used to reduce inflammation and control symptoms in neonatal-onset severe multisystemic autoinflammatory disease with increased IL18.

3. Immunosuppressants: Immunosuppressants such as cyclosporine, azathioprine, and methotrexate can be used to reduce inflammation and control symptoms in neonatal-onset severe multisystemic autoinflammatory disease with increased IL18.

4. Biologic agents:

1. Genetic predisposition: mutations in the NLRP3 gene, which encodes the inflammasome protein, are the most common cause of Neonatal-onset severe multisystemic autoinflammatory disease.

2. Family history: having a family member with the condition increases the risk of developing Neonatal-onset severe multisystemic autoinflammatory disease.

3. Ethnicity: Neonatal-onset severe multisystemic autoinflammatory disease is more common in certain ethnic groups, such as Ashkenazi Jews.

4. Gender: Neonatal-onset severe multisystemic autoinflammatory disease is more common in males than females.

5. Increased IL18: elevated levels of interleukin-18 (IL-18) have been associated with Neonatal-onset severe multisystem

At this time, there is no known cure for Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18. However, there are medications that can be used to manage the symptoms of the disease. These medications include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic agents such as anakinra, tocilizumab, and canakinumab. It is important to speak with your doctor to determine the best treatment plan for your individual situation.